Family history of prostate cancer and the incidence of ERG- and phosphatase and tensin homolog-defined prostate cancer.
PTEN
TMPRSS2:ERG
family history
molecular subtypes
prostate cancer
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
15 05 2020
15 05 2020
Historique:
received:
27
01
2019
revised:
18
06
2019
accepted:
28
06
2019
pubmed:
19
7
2019
medline:
23
9
2020
entrez:
19
7
2019
Statut:
ppublish
Résumé
Family history is among the strongest known risk factors for prostate cancer (PCa). Emerging data suggest molecular subtypes of PCa, including two somatic genetic aberrations: fusions of androgen-regulated promoters with ERG and, separately, phosphatase and tensin homolog (PTEN) loss. We examined associations between family history and incidence of these subtypes in 44,126 men from the prospective Health Professionals Follow-up Study. ERG and PTEN status were assessed by immunohistochemistry. Multivariable competing risks models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for associations between self-reported family history of PCa and molecular subtypes of disease. Thirteen percent of men had a positive family history of PCa at baseline. During a median follow-up of 18.5 years, 5,511 PCa cases were diagnosed. Among them, 888 were assayed for ERG status (47% ERG-positive) and 715 were assayed for PTEN loss (14% PTEN null). Family history was more strongly associated with risk of ERG-negative (HR: 2.15; 95% CI: 1.71-2.70) than ERG-positive (HR: 1.49; 95% CI: 1.13-1.95) disease (p
Identifiants
pubmed: 31318977
doi: 10.1002/ijc.32577
pmc: PMC7905843
mid: NIHMS1669003
doi:
Substances chimiques
Biomarkers, Tumor
0
ERG protein, human
0
Transcriptional Regulator ERG
0
PTEN Phosphohydrolase
EC 3.1.3.67
PTEN protein, human
EC 3.1.3.67
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
2694-2702Subventions
Organisme : NCI NIH HHS
ID : P50 CA090381
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA167552
Pays : United States
Organisme : NIH HHS
ID : P50 CA090381
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NIH HHS
ID : U01 CA167552
Pays : United States
Organisme : NIH HHS
ID : R25 CA112355
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA113913
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009001
Pays : United States
Organisme : NIH HHS
ID : R01 CA141298
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA141298
Pays : United States
Organisme : NIH HHS
ID : R01 CA136578
Pays : United States
Organisme : NCI NIH HHS
ID : R25 CA112355
Pays : United States
Organisme : NIH HHS
ID : T32 CA09001
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA136578
Pays : United States
Informations de copyright
© 2019 UICC.
Références
Am J Epidemiol. 2005 Nov 15;162(10):975-82
pubmed: 16207808
Biometrics. 1995 Jun;51(2):524-32
pubmed: 7662841
Am J Epidemiol. 2015 May 1;181(9):706-13
pubmed: 25852077
Hum Mol Genet. 2016 Dec 15;25(24):5490-5499
pubmed: 27798103
J Natl Cancer Inst. 2015 Nov 27;108(2):
pubmed: 26615022
Cancer Epidemiol Biomarkers Prev. 2016 May;25(5):745-9
pubmed: 26941365
Urology. 2001 Feb;57(2):217-24
pubmed: 11182324
Am J Epidemiol. 2017 Dec 15;186(12):1352-1361
pubmed: 28633309
Br J Cancer. 2010 Feb 16;102(4):678-84
pubmed: 20104229
Histopathology. 2012 Mar;60(4):645-52
pubmed: 22260502
Prostate. 2011 Apr;71(5):489-97
pubmed: 20878952
Prostate Cancer Prostatic Dis. 2013 Jun;16(2):209-15
pubmed: 23545904
JAMA. 2016 Jan 5;315(1):68-76
pubmed: 26746459
Urology. 2002 Nov;60(5):756-9
pubmed: 12429290
Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1497-509
pubmed: 22736790
Arch Intern Med. 2002 Sep 23;162(17):1985-93
pubmed: 12230422
Br J Cancer. 2007 Sep 3;97(5):678-85
pubmed: 17700571
Curr Cancer Drug Targets. 2011 Jun;11(5):536-47
pubmed: 21486223
Prostate. 2017 Feb;77(3):282-290
pubmed: 27753122
Oncotarget. 2016 Oct 18;7(42):68371-68384
pubmed: 27634912
Hum Mol Genet. 2004 Apr 1;13 Spec No 1:R103-21
pubmed: 14749351
Am J Clin Nutr. 2016 Mar;103(3):851-60
pubmed: 26817504
Oncotarget. 2017 Jul 10;8(39):65566-65576
pubmed: 29029453
Br J Cancer. 2013 Jun 25;108(12):2582-9
pubmed: 23695019
Int J Cancer. 2007 Oct 1;121(7):1571-8
pubmed: 17450530
Sci Signal. 2010 Apr 13;3(117):ra29
pubmed: 20388916
Cancer Epidemiol Biomarkers Prev. 2018 Feb;27(2):193-200
pubmed: 29167279
Clin Cancer Res. 2018 Dec 1;24(23):5910-5917
pubmed: 30082473
Prostate Cancer Prostatic Dis. 2016 Mar;19(1):53-6
pubmed: 26503111
Asian J Androl. 2016 Jul-Aug;18(4):533-42
pubmed: 26975494
Eur Urol. 2019 Jul;76(1):33-40
pubmed: 30301696
Psychooncology. 2004 Feb;13(2):80-5
pubmed: 14872526
Mol Clin Oncol. 2014 Nov;2(6):982-986
pubmed: 25279185
Cancer Res. 2009 Jan 15;69(2):640-6
pubmed: 19147579
Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2303-10
pubmed: 24812039
Mod Pathol. 2009 Aug;22(8):1083-93
pubmed: 19407851
Am J Pathol. 2000 Oct;157(4):1123-8
pubmed: 11021816
Prostate. 2008 Oct 1;68(14):1582-91
pubmed: 18646000
Br J Cancer. 2007 Dec 17;97(12):1690-5
pubmed: 17971772
Clin Cancer Res. 2011 Oct 15;17(20):6563-73
pubmed: 21878536
Cancer Discov. 2015 Aug;5(8):878-91
pubmed: 26034056
Semin Cell Dev Biol. 2004 Apr;15(2):171-6
pubmed: 15209376
Cell. 2015 Nov 5;163(4):1011-25
pubmed: 26544944
Neoplasia. 2008 Feb;10(2):177-88
pubmed: 18283340
Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):2027-31
pubmed: 24925673
J Natl Cancer Inst. 2010 Sep 8;102(17):1336-43
pubmed: 20724726
Mod Pathol. 2008 Dec;21(12):1451-60
pubmed: 18500259
Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5246-50
pubmed: 9560261
Health Psychol. 2013 Nov;32(11):1158-69
pubmed: 23527518
Eur Urol. 2017 May;71(5):697-700
pubmed: 27477529